Current Editions
FDA layoffs could cripple agency, former FDA commissioners say
Reviews of novel drugs could be disrupted, long-term plans for FDA unclear
Politics, Policy & Law
Product Development
VEGF bispecifics make inroads in other cancers, and more: Clinical Report
Plus: The week’s gainers and decliners after data
Politics, Policy & Law
‘Pandemonium’ at FDA
Peter Stein pushed out as head of OND; thousands of layoffs
Management Tracks
Change at the top for Phathom as Basta replaces Curran
Plus: Updates from Nuage, GV, Inhibrx, Lyell, Repare, Adcendo, ITM Isotope, Transgene and Novartis
BioCentury ISSN 1097-7201